SGTX Stock Analysis
SG
Uncovered
Sigilon Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2020-12-04. The firm has developed its Shielded Living Therapeutics (SLTx platform), which is comprised of two primary elements: the cells and the sphere. The Company’s products candidate includes SIG-005, SIG-007, SIG-002 and SIG-001. SIG-005 is being developed to treat the non-neurological manifestations of mucopolysaccharidosis type 1 in patients with the disease. SIG-007 product is designed to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease. SIG-002 product is designed to replace islet cells for the treatment of Type 1 Diabetes. SIG-001 product candidate is designed to prevent bleeding episodes in patients with moderate to severe Hemophilia A.